| This open-label, nonrandomized study investigating the pharmacokinetics, safety, and tolerability of a single 0.5 mg dose of ocedurenone in participants with or without moderate hepatic impairment determined that no dose adjustment is required in patients with moderate hepatic impairment. |
| Ocedurenone was safe and well-tolerated in all participants. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.